title: Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.
abstract: Therapeutic cancer vaccines represent a new class of agents in the treatment of cancer. Sipuleucel-T is an antigen-presenting cell-based vaccine that recently demonstrated a significant 4.8-month improvement in overall survival in advanced prostate cancer patients and was well tolerated. The findings of that study have been met with skepticism, primarily because the agent did not change initial disease progression and yet led to longer survival. Although the commonly accepted treatment paradigm suggests that treatments should initially decrease tumor volume, perhaps vaccines work differently. Vaccines may induce delayed responses not seen in the first few months of therapy or they may initiate a dynamic immune response that ultimately slows the tumor growth rate, resulting in longer survival. Subsequent therapies may also combine with the induced immune response, resulting in a combination that is more effective than conventional treatments alone. Also, other treatments may alter tumor-associated antigen expression, enhancing the immune response. Future trials are currently planned to investigate these hypotheses; however, the results of the sipuleucel-T vaccine in prostate cancer should not be dismissed. Results with another vaccine in prostate cancer are similar, perhaps suggesting a class effect. In a broader context, clinicians may need to reconsider how they measure success. Several agents have been approved that produce superior disease progression results, but do not affect overall survival. Given the toxicity and costs of cancer therapies, perhaps studies should put more weight on long-term survival endpoints than on short-term endpoints that may be less consequential.
authors.affiliation: Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: Ravi A
authors.initials: RA
authors.lastname: Madan
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
authors.forename: Tito
authors.initials: T
authors.lastname: Fojo
authors.forename: William L
authors.initials: WL
authors.lastname: Dahut
mesh_terms: D019985:Benchmarking; D019496:Cancer Vaccines / Q000627:therapeutic use*; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality / Q000628:therapy*; D013997:Time Factors
chemical_list: D019496:Cancer Vaccines; D017430:Prostate-Specific Antigen
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: Nat Clin Pract Oncol. 2007 Mar;4(3):136-7
references.pmid: 17327854
references.citation: Clin Cancer Res. 2000 Jun;6(6):2175-82
references.pmid: 10873066
references.citation: Clin Cancer Res. 2008 Jun 1;14(11):3536-44
references.pmid: 18519787
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):3776-82
references.pmid: 17606707
references.citation: Semin Immunol. 2010 Jun;22(3):113-24
references.pmid: 20403709
references.citation: Ann Pharmacother. 2008 Jan;42(1):91-8
references.pmid: 18094343
references.citation: Eur Urol. 2009 May;55(5):1112-23
references.pmid: 19042080
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
references.pmid: 16344461
references.citation: Br J Radiol. 2004 Jan;77(913):74-5
references.pmid: 14988145
references.citation: JAMA. 2005 Jul 13;294(2):238-44
references.pmid: 16014598
references.citation: Cancer. 2008 Nov 1;113(9):2478-87
references.pmid: 18785254
references.citation: J Clin Oncol. 2003 Aug 15;21(16):3127-32
references.pmid: 12915604
references.citation: Curr Opin Mol Ther. 2002 Feb;4(1):76-9
references.pmid: 11883698
references.citation: Eur J Cancer. 2006 May;42(8):1031-9
references.pmid: 16616487
references.citation: J Clin Oncol. 2011 Apr 1;29(10):1252-60
references.pmid: 21383283
references.citation: J Clin Invest. 2008 Jun;118(6):1991-2001
references.pmid: 18523649
references.citation: J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8
references.pmid: 19564563
references.citation: Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):878-87
references.pmid: 16467102
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3089-94
references.pmid: 16809734
references.citation: Cancer. 1981 Jan 1;47(1):207-14
references.pmid: 7459811
references.citation: Clin Cancer Res. 2005 Mar 15;11(6):2416-26
references.pmid: 15788693
references.citation: J Clin Oncol. 2009 Jun 10;27(17):2766-71
references.pmid: 19380448
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Clin Cancer Res. 2008 May 15;14(10):3060-9
references.pmid: 18483372
references.citation: Cancer Res. 2001 May 1;61(9):3689-97
references.pmid: 11325840
references.citation: N Engl J Med. 2007 Dec 27;357(26):2666-76
references.pmid: 18160686
references.citation: Novartis Found Symp. 1998;215:92-8; discussion 98-102, 186-90
references.pmid: 9760573
references.citation: Clin Cancer Res. 2005 May 1;11(9):3353-62
references.pmid: 15867235
references.citation: Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77
references.pmid: 16467101
references.citation: J Clin Oncol. 2000 Dec 1;18(23):3894-903
references.pmid: 11099318
references.citation: Prostate. 2004 Aug 1;60(3):197-204
references.pmid: 15176049
references.citation: Oncology (Williston Park). 2009 May;23(6):546-53
references.pmid: 19544696
references.citation: Cancer Immunol Immunother. 2010 May;59(5):663-74
references.pmid: 19890632
references.citation: N Engl J Med. 2004 Oct 7;351(15):1513-20
references.pmid: 15470214
references.citation: Nat Immunol. 2002 Jul;3(7):611-8
references.pmid: 12087419
references.citation: Expert Opin Investig Drugs. 2009 Jul;18(7):1001-11
references.pmid: 19548854
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: Vaccine. 2007 Sep 27;25 Suppl 2:B89-96
references.pmid: 17573164
references.citation: J Clin Oncol. 2008 Mar 1;26(7):1148-59
references.pmid: 18309951
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Clin Cancer Res. 2005 Jun 15;11(12):4430-6
references.pmid: 15958627
references.citation: BJU Int. 2009 Jun;103(12):1636-40
references.pmid: 19154507
references.citation: Oncologist. 2008 Oct;13(10):1046-54
references.pmid: 18838440